Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth

Journal of Immunology

Volumn 162, Issue 11, 1999, Pages 6663-6670

  Martin, Brian K ^a   Frelinger, John G ^b   Ting, Jenny P Y ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ARTICLE; CANCER INHIBITION; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LUNG TUMOR; PRIORITY JOURNAL; TRANSACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD86; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA; DRUG SYNERGISM; GENE THERAPY; GENES, MHC CLASS II; GROWTH INHIBITORS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; NUCLEAR PROTEINS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0033153498     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Antonia, S. J., M. Extermann, and R. A. Flavell. 1998. Immunologic nonresponsiveness to tumors. Crit. Rev. Oncog. 9:35.
2. Greenfield, E. A., K. A. Nguyen, and V. K. Kuchroo. 1998. CD28/B7 costimulation: a review. Crit. Rev. Immunol. 18:389.
3. Grewal, I. S., and R. A. Flavell. 1996. The role of CD40 ligand in costimulation and T-cell activation. Immunol. Rev. 153:85.
4. Freeman, G. J., A. S. Freedman, J. M. Segil, G. Lee, J. F. Whitman, and L. M. Nadler. 1989. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143:2714.
5. Freeman, G. J., G. S. Gray, C. D. Gimmi, D. B. Lombard, L. J. Zhou, M. White, J. D. Fingeroth, J. G. Gribben, and L. M. Nadler. 1991. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174:625.
6. Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. W. Ng, V. A. Restivo, Jr., L. A. Lombard, G. S. Gray, and L. M. Nadler. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909.
7. Azuma, M., D. Ito, H. Yagita, K. Okumura, J. H. Phillips, L. L. Lanier, and C. Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76.
8. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellström, and K. E. Hellström. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
9. Gajewski, T. F., F. Fallarino, C. Uyttenhove, and T. Boon. 1996. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156:2909.
10. Matulonis, U., C. Dosiou, G. Freeman, C. Lamont, P. Mauch, L. M. Nadler, and J. D. Griffin. 1996. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1126.
11. Chamberlain, R. S., M. W. Carroll, V. Bronte, P. Hwu, S. Warren, J. C. Yang, M. Nishimura, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1996. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res. 56:2832.
12. + T lymphocytes in the P815 tumor system in vitro. J. Immunol. 156:465.
13. Leong, C. C., J. V. Marley, S. Loh, N. Milech, B. W. Robinson, and M. J. Garlepp. 1997. Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma. Int. J. Cancer 71:476.
14. Hodge, J. W., S. Abrams, J. Schlom, and J. A. Kantor. 1994. Induction of anti-tumor immunity by recombinanl vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 54:5552.
15. Yang, G., K. E. Hellstrom, I. Hellstrom, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794.
16. La Motte, R. N., M. A. Rubin, E. Barr, J. M. Leiden, J. A. Bluestone, and M. B. Mokyr. 1996. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol. Immunother. 42:161.
17. Martin-Fontecha, A., F. Cavallo, M. Bellone, S. Heltai, G. Iezzi, P. Tornaghi, N. Nabavi, G. Forni, P. Dellabona, and G. Casorati. 1996. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur. J. Immunol. 26:1851.
18. Cohen, E. P., and T. S. Kim. 1994. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin. Cancer Biol. 5:419.
19. Hui, K., F. Grosveld, and H. Festenstein. 1984. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311: 750.
20. Tanaka, K., K. J. Isselbacher, G. Khoury, and G. Jay. 1985. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 228:26.
21. Wallich, R., N. Bulbuc, G. J. Hammerling, S. Katzav, S. Segal, and M. Feldman. 1985. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315:301.
22. Ostrand-Rosenberg, S. 1994. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 6:722.
23. York, I. A., and K. L. Rock 1996. Antigen processing and presentation by the class I major histocompatibility complex. Annu. Rev. Immunol. 14:369.
24. Restifo, N. P., F. Esquivel, Y. Kawakami, J. W. Yewdell, J. J. Mule, Rosenberg, S. A., and J. R. Bennink. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:265.
25. Cromme, F. V., P. F. van Bommel, J M. Walboomers, M. P. Gallee, P. L. Stern, P. Kenemans, T. J. Helmerhorst, M. J. Stukart, and C. J. Meijer. 1994. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br. J. Cancer 69:1176.
26. German, R. N., F. Castellino, R. Han, E. S. Reis, C. P. Romagnoli, S. Sadegh-Nasseri, and O. M. Zhong. 1996. Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules. Immunol. Rev. 151:5.
27. Steimle, V., L. A. Otten, M. Zufferey, and B. Mach. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135.
28. Steimle, V., C. A. Siegrist, A. Mottet, B. Lisowska-Grospierre, and B. Mach. 1994. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science 265:106.
29. Chin, K.-C., C. Mao, C. Skinner, J. L. Riley, K. L. Wright, C. S. Moreno, G. R. Stark, J. M. Boss, and J. P.-Y. Ting. 1994. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity 1:687.
30. Chang, C. H., J. D. Fontes, M. Peterlin, and R. A. Flavell. 1994. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J. Exp. Med. 180:1367.
31. Chang, C. H., and R. A. Flavell. 1995. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J. Exp. Med. 181: 765.
32. Chang, C.-H., S. Guerder, S.-C. Hong, W. van Ewijk, and R. A. Flavell. 1996. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 4:167.
33. Armstrong, T. D., V. K. Clements, B. K. Martin, J. P. Y. Ting, and S. Ostrand-Rosenberg. 1997. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl. Acad. Sci. USA 94:6886.
34. Hershberg, R. M., D. H. Cho, A. Youakim, M. B. Bradley, J. S. Lee, P. E. Framson, and G. T. Nepom. 1998. Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells. J. Clin. Invest. 102:792.
35. Sartoris, S., M. T. Valle, A. L. Barbaro, G. Tosi, T. Cestari, A. D'Agostino, A. M. Megiovanni, F. Manca, and R. S. Accolla. 1998. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity. J. Immunol. 161:814.
36. Siegrist, C. A., E. Martinez-Soria, I. Kern, and B. Mach. 1995. A novel antigen processing defective phenotype in MHC class II positive CIITA transfectants is corrected by interferon-γ. J. Exp. Med. 182:1793.
37. Martinez-Soria, E., C. A. Siegrist, and B. Mach. 1996. Highly efficient peptide binding and T cell activation by MHC class II molecules of CIITA-transfected cells. Int. Immunol. 8:543.
38. Martin, B. K., K.-C. Chin, C. A. Skinner, J. C. Olsen, A. Dey, K. Ozato, and J. P.-Y. Ting. 1997. Induction of MHC class I expression by the MHC class II transactivator (CIITA). Immunity 6:591.
39. Gobin, S. J. P., A. Peijnenburg, V. Keijsers, and P. J. van den Elsen. 1997. Site a is crucial for two routes of IFN-γ-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity 6:601.
40. Reyburn, H., O. Mandelboim, M. Vales-Gomez, E. G. Sheu, L. Pazmany, D. M. Davis, and J. L. Strominger. 1997. Human NK cells: their ligands, receptors and functions. Immunol. Rev. 155:119.
41. Lanier, L. L. 1998. NK cell receptors. Annu. Rev. Immunol. 16:359.
42. Pulaski, B. A., A. J. McAdam, E. K. Hutter, S. Biggar, E. M. Lord, and J. G. Frelinger. 1993. Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res. 53:2112.
43. Yeh, K. Y., B. A. Pulaski, M. L. Woods, A. J. McAdam, A. A. Gaspari, J. G. Frelinger, and E. M. Lord. 1995. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell. Immunol. 165:217.
44. McAdam, A. J., B. A. Pulaski, S. S. Harkins, E. K. Hutter, E. M. Lord, and J. G. Frelinger. 1995. Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-γ on generation of murine tumor-reactive cytoloxic cells. Int. J. Cancer 61:628.
45. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065.
46. Chong, H., G. Hutchinson, I. R. Hart, and R. G. Vile. 1996. Expression of costimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Hum. Gene Ther. 7:1771.
47. Lanier, L. L., S. O'Fallon, C. Somoza, J. H. Phillips, P. S. Linsley, K. Okumura, D. Ito, and M. Azuma. 1995. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154:97.
48. Bei, R., V. Guptill, L. Masuelli, S. V. Kashmiri, R. Muraro, L. Frati, J. Schlom, and J. Kantor. 1998. The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice. J. Immunother. 21:159.
49. Samuel, J., W. A. Budzynski, M. A. Reddish, L. Ding, G. L. Zimmermann, M. J. Krantz, R. R. Koganty, and B. M. Longenecker. 1998. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int. J. Cancer 75:295.